Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - April 23, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/16/17 - Drugmakers tussle over opioid bill's price tag
COLUMBUS As Ohio debated whether to require Medicaid and other insurers to cover new, higher priced prescription painkillers, records show pharmaceutical lobbyists pushed officials to lower their estimates of what it would cost the state. The estimated taxpayer cost of the Ohio proposal was adjusted significantly down over seven months as lobbyi
4/16/17 - New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS palivizumab May Result in Reduced Overall Costs in Preterm Infants Born at 29-32 wGA Who Are...
New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS palivizumab May Result in Reduced Overall Costs in Preterm Infants Born at 29-32 wGA Who Are Less Than Three Months of Age. By a News Reporter-Staff News Editor at Heart Disease Weekly AstraZeneca announced new results data which evaluated the cost-effectiveness of SYNAGIS for respirat
4/16/17 - Records: Drugmakers tussle over Ohio opioid bill's price
COLUMBUS, Ohio- As Ohio debated whether to require Medicaid and other insurers to cover new, higher priced prescription painkillers, records show pharmaceutical lobbyists pushed officials to lower their estimates of what it would cost the state. The estimated taxpayer cost of the Ohio proposal was adjusted significantly down over seven months as lo
4/16/17 - Records: Drugmakers tussle over Ohio opioid bill's price tag
COLUMBUS, Ohio As Ohio debated whether to require Medicaid and other insurers to cover new, higher priced prescription painkillers, records show pharmaceutical lobbyists pushed officials to lower their estimates of what it would cost the state. The estimated taxpayer cost of the Ohio proposal was adjusted significantly down over seven months as
4/15/17 - Arkansas executions: health giant sues state as federal judge issues injunction
A US healthcare giant has accused the state of Arkansas of effectively lying to it over the sale of a pharmaceutical drug that the Republican governor had been poised to use in a historic killing spree of eight prisoners in 11 days.. Related: Arkansas executions: drugmakers don't want their medicines used in killings. The governor had scheduled a s
4/15/17 - Beantown biopharma campaign takes over Kendall Square in agency blitz [T-break Tech (Middle East)]
Boston subway ridersmake that Boston T riderspassing through Kendall Square will be treated to local biopharma banter this month. To showcase its capabilities to the pharma and biotech crowd in Beantown, Precision Medicine Group has staged a station takeover combining Boston lore with biopharma messages on bright yellow signage all around.
4/15/17 - Can California's 'right to try' law help save terminal patients? [The Sacramento Bee]
April 15 Brynnlee and Archer Thomas, ages 4 and 2, didn't hesitate on a recent morning when their grandmother, Shelly Hoover, called for help removing her socks. Since being diagnosed with Lou Gehrig's disease in 2013, the Lincoln resident has made every effort to keep life vibrant even as she slowly loses control of her own muscles. Hoover, an e
4/15/17 - Company Spotlight: Incyte
WASHINGTON- Shares of Incyte Corp. have gained nearly 38% year-to-date compared to a modest 8.77% rise in the iShares NASDAQ Biotech Index ETF during the same period. The Company received its first FDA approval in November 2011 and it was for Jakafi, a JAK1 and JAK2 inhibitor, indicated for the treatment of patients with myelofibrosis and polycythe
4/15/17 - FDA calls for more tests for Lily-Incyte arthritis drug
Eli Lilly and Company and Incyte Corp., Wilmington, announced that the U.S. Food and Drug Administration denied approval of an arthritis drug, citing the need for additional trials. has issued a complete response letter for the New Drug Application of the investigational medicine. The FDA indicated that additional clinical data are needed to determ
4/15/17 - House, Senate Health Committee Leaders Release Discussion Draft of FDA User Fees Reauthorization
The Food and Drug Administration Reauthorization Act of 2017 renews FDA's authority to collect user fees from the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, and several vital programs at the FDA. If the agreements are not reauthorized before the August work period, the agency will be forced to send layoff no
4/15/17 - Lilly`s Rheumatoid Arthritis Pill Rejected by Regulators [Sudan Tribune]
Eli Lilly said U.S. regulators have rejected its much-anticipated pill for the immune disorder rheumatoid arthritis, the drugmaker`s second drug development setback since November. Lilly said it disagrees with FDA`s conclusions but will work with the agency on a plan to eventually get the drug, baracitinib, approved for U.S. patients. Eli Lilly& Co
4/15/17 - Reps. Paulsen, Kind Introduce Bill to Reduce Obesity Among Seniors
Congressman Erik Paulsen and Congressman Ron Kind introduced the Treat and Reduce Obesity Act to expand access to treatment options for Medicare beneficiaries afflicted with obesity. When Medicare Part D was created in 2006, there were no widely-accepted FDA- approved obesity drugs on the market. The Treat and Reduce Obesity Act would remove the ex
4/15/17 - Senate, House Health Committee Leaders Release Discussion Draft of FDA User Fees Reauthorization
The Food and Drug Administration Reauthorization Act of 2017 renews FDA's authority to collect user fees from the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, and several vital programs at the FDA. If the agreements are not reauthorized before the August work period, the agency will be forced to send layoff no
4/15/17 - U.S. FDA Issues Warning Letter To Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)'s Over Manufacturing Plant In China
The U.S. Food and Drug Administration (FDA) have flagged concerns over the mechanized controls at Teva's Pharmaceutical industries Ltd (NYSE:TEVA) facility in China. The FDA has issued the company with a warning letter on April 10 following a regulatory inspection carried out at the plant in September last year. Teva, the Israel's largest firm
4/15/17 - U.S. firm Zoetis buys Irish pet care biopharma company, Nexvet [Big News Network (United Arab Emirates)]
DUBLIN, Ireland- Irish clinical stage biopharma start-up Nexvet has been acquired by U.S. animal health firm Zoetis. The Irish pet medication group based in Tullamore develops drugs for companion animals- dogs, cats and horses and was established by entrepreneur Mark Heffernan. Zoetis has reportedly agreed to p ay $6.72 a share through a wholly own
4/15/17 - Vermont Attorney General Urges Eligible Vermont Residents to Submit Claims for Provigil Settlement
MONTPELIER, Vt., April 14 Vermont Attorney General xxx issued the following news release:. Attorney General TJ Donovan urges Vermont residents to file claims on a $125 million multistate settlement that provides $35 million to consumers who paid for the brand-name drug Provigil or generic modafinil from June 24, 2006, to March 31, 2012. In August
4/14/17 - "Paramyxovirus Immunogens and Related Materials and Methods" in Patent Application Approval Process (USPTO 20170080081)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Li, Jianrong; Zhang, Yu; Wang, Rongzhang, filed on December 1, 2016, was made available online on March 30, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Ohio State Innovat
4/14/17 - 2-Day In-Person Seminar by Ex-FDA Official: FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials (Tampa, FL, United States - May 18-19, 2017) - Research and Markets
Research and Markets has announced the addition of the " FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials: 2- Day In-Person Seminar by Ex-FDA Official" conference to their offering. Review the FDA recommendations and requirements for implementing a compliant program for the phase 1 clinical program. The following topics will be d
4/14/17 - AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network ORIEN Avatar Research Program
By a News Reporter-Staff News Editor at Drug Week- AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced that AbbVie has joined the Oncology Research Information Exchange Network Avatar Research Program. ORIEN Avatar is a collaboration between the 15 leading U.S. cancer hospitals that
4/14/17 - After a clinical trial on Midazolam for seizures, emergency use of the drug rises
By a News Reporter-Staff News Editor at Health& Medicine Week ANN ARBOR, Mich.- For status epilepticus patients who experience seizures outside of the hospital, treatment administered on an ambulance is an important component of their overall care. "When people experience seizures we frequently call an ambulance, and they're treated with a benzo
4/14/17 - An Application for the Trademark "SEROQUEL XR" Has Been Filed by AstraZeneca Pharmaceuticals
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "SEROQUEL XR" by Cara M. Kearney, representing AstraZeneca Pharmaceuticals. The owner/registrar information for this application is: Cara M. Kearney, AstraZeneca Pharmace
4/14/17 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Mar. 24, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on March 23, 2017. The SEC file number is 0001628280-17-002872.. A U.S. Securities and Exchange Commission filing is a formal
4/14/17 - Arbutus Biopharma Corp. Files SEC Form 8-K, Current Report (Mar. 28, 2017)
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Arbutus Biopharma Corp. was posted on March 27, 2017. The SEC file number is 0001628280-17-002951.. A U.S. Securities and Exchange Commission filing is a formal
4/14/17 - Arbutus Injunction Survives Attempted Appeal by Acuitas [Sport360]
-Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that a justice of the Court of Appeal for British Columbia denied an attempt by Acuitas Therapeutics to appeal the injunction issued by the Supreme Court of British Columbia, which prevents Acuitas from any further licensing of Arbut
4/14/17 - Baylor College of Medicine, Houston, Ionis Pharmaceuticals, Carlsbad, Calif., Assigned Patent for Modulation of UBE3A-ATS Expression
Baylor College of Medicine, Houston, and Ionis Pharmaceuticals, Carlsbad, California, have been assigned a patent developed by four co-inventors for the "modulation of UBE3A-ATS expression." The co-inventors are Frank Rigo, Carlsbad, California, Amanda Ward, Carlsbad, California, Linyan Meng, Houston, and Arthur L. Beaudet, Houston. Written by Devi
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415